REPL
Replimune Group Inc
$
5.290
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.4851
Open
5.390
VWAP
5.22
Vol
4.86M
Mkt Cap
412.92M
Low
5.010
Amount
25.35M
EV/EBITDA(TTM)
--
Total Shares
61.42M
EV
81.73M
EV/OCF(TTM)
--
P/S(TTM)
--
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
--
--
-0.862
+26.72%
--
--
-0.802
+1.48%
--
--
-0.752
-8.33%
Estimates Revision
The market is revising Downward the revenue expectations for Replimune Group, Inc. (REPL) for FY2026, with the revenue forecasts being adjusted by -84.89% over the past three months. During the same period, the stock price has changed by -32.70%.
Revenue Estimates for FY2026
Revise Downward
-84.89%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
+7.77%
In Past 3 Month
Stock Price
Go Down
-32.70%
In Past 3 Month
9 Analyst Rating
-18.90% Downside
Wall Street analysts forecast REPL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 4.29 USD with a low forecast of 2.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
6 Hold
1 Sell
Hold
-18.90% Downside
Current: 5.290
Low
2.00
Averages
4.29
High
9.00
-18.90% Downside
Current: 5.290
Low
2.00
Averages
4.29
High
9.00
Cantor Fitzgerald
Neutral -> Overweight
upgrade
2025-07-30
Reason
Cantor Fitzgerald
Price Target
2025-07-30
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald upgraded Replimune to Overweight from Neutral.
Cantor Fitzgerald
Li Watsek
Neutral -> Overweight
upgrade
$12
2025-07-30
Reason
Cantor Fitzgerald
Li Watsek
Price Target
$12
2025-07-30
upgrade
Neutral -> Overweight
Reason
As previously reported, Cantor Fitzgerald analyst Li Watsek upgraded Replimune to Overweight from Neutral following news that Vinay Prasad has departed the FDA. The firm's sense is that the "surprise" complete response letter issued on July 22 was the result of senior leadership, likely Prasad, overruling the review team and it sees the exit of the doctor as "removing a major obstacle" for the potential of the CRL to be overturned. The firm, which sees the "greatly improved" odds of RP1 receiving accelerated approval, expects shares to trade to pre-CRL levels over $12 per share in the case the CRL is overturned, the analyst tells investors.
H.C. Wainwright
Robert Burns
Buy -> Neutral
downgrade
2025-07-23
Reason
H.C. Wainwright
Robert Burns
Price Target
2025-07-23
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Robert Burns downgraded Replimune to Neutral from Buy without a price target after the FDA issued a complete response letter for RP1 in anti-PD1 failed melanoma patients. RP1's path to market "just got painfully longer," the analyst tells investors in a research note.
BMO Capital
Outperform -> Underperform
downgrade
$27 -> $2
2025-07-22
Reason
BMO Capital
Price Target
$27 -> $2
2025-07-22
downgrade
Outperform -> Underperform
Reason
BMO Capital double downgraded Replimune to Underperform from Outperform with a price target of $2, down from $27. While the firm continues to think that RP1 represents a \"real drug,\" the simple reality is that Replimune will likely need to re-run its clinical studies to get to approval and may not have enough cash on its books to get there, the analyst tells investors in a research note. The firm added that it believes more clarity on a path forward and significant restructuring are needed, while Replimune will likely underperform its peer group in the interim.
Wedbush
Outperform -> Neutral
downgrade
$19 -> $4
2025-07-22
Reason
Wedbush
Price Target
$19 -> $4
2025-07-22
downgrade
Outperform -> Neutral
Reason
Wedbush downgraded Replimune to Neutral from Outperform with a price target of $4, down from $19.
Piper Sandler
Overweight -> Neutral
downgrade
$22 -> $3
2025-07-22
Reason
Piper Sandler
Price Target
$22 -> $3
2025-07-22
downgrade
Overweight -> Neutral
Reason
Piper Sandler downgraded Replimune to Neutral from Overweight with a price target of $3, down from $22.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Replimune Group Inc (REPL.O) is -2.01, compared to its 5-year average forward P/E of -8.35. For a more detailed relative valuation and DCF analysis to assess Replimune Group Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.35
Current PE
-2.01
Overvalued PE
-1.97
Undervalued PE
-14.73
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.93
Undervalued EV/EBITDA
-9.29
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
4.32
Current PS
50.76
Overvalued PS
25.64
Undervalued PS
-16.99
Financials
Annual
Quarterly
FY2026Q1
YoY :
+57.62%
-90.42M
Operating Profit
FY2026Q1
YoY :
+61.22%
-86.69M
Net Income after Tax
FY2026Q1
YoY :
+21.79%
-0.95
EPS - Diluted
FY2026Q1
YoY :
+56.89%
-79.76M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 386.03% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
603.6K
USD
6
6-9
Months
124.2K
USD
1
0-12
Months
134.2K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
691.9K
Volume
3
6-9
Months
1.6M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
5
6.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 386.03% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
603.6K
USD
6
6-9
Months
124.2K
USD
1
0-12
Months
134.2K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
REPL News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
08:05:56
Replimune sees cash runway into 4Q26
2025-08-07
08:04:32
Replimune reports Q1 EPS (95c), consensus (81c)
2025-07-30 (ET)
2025-07-30
12:05:45
Video: Why Replimune Is Soaring Today
Sign Up For More Events
Sign Up For More Events
News
7.0
08-10GlobenewswireROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
7.0
08-09PRnewswireREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
7.0
08-09PRnewswireFaruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL
Sign Up For More News
People Also Watch
MTAL
MAC Copper Ltd
12.080
USD
+0.08%
ASTE
Astec Industries Inc
43.185
USD
+0.66%
AC
Associated Capital Group Inc
36.370
USD
+0.86%
CPF
Central Pacific Financial Corp
26.900
USD
+1.74%
TCPC
BlackRock TCP Capital Corp
7.070
USD
+1.87%
MEG
Montrose Environmental Group Inc
26.130
USD
+6.52%
CRML
Critical Metals Corp
4.630
USD
+9.46%
SHLS
Shoals Technologies Group Inc
4.720
USD
-1.05%
SWIM
Latham Group Inc
7.380
USD
+0.96%
MLR
Miller Industries Inc
39.750
USD
+0.03%
FAQ
What is Replimune Group Inc (REPL) stock price today?
The current price of REPL is 5.29 USD — it has decreased -3.47 % in the last trading day.
What is Replimune Group Inc (REPL)'s business?
What is the price predicton of REPL Stock?
What is Replimune Group Inc (REPL)'s revenue for the last quarter?
What is Replimune Group Inc (REPL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Replimune Group Inc (REPL)'s fundamentals?
How many employees does Replimune Group Inc (REPL). have?